Cargando…
Current perspectives on cardiovascular outcome trials in diabetes
Cardiovascular disease (CVD) is one of the most common diabetes-associated complications, as well as a leading cause for death in type 2 diabetes patients (T2D). Despite the well-known correlation between the two, up until the 2008 FDA industry guidance for licensing of new anti-hyperglycemic drugs,...
Autores principales: | Schnell, Oliver, Rydén, Lars, Standl, Eberhard, Ceriello, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045635/ https://www.ncbi.nlm.nih.gov/pubmed/27716274 http://dx.doi.org/10.1186/s12933-016-0456-8 |
Ejemplares similares
-
Updates on cardiovascular outcome trials in diabetes
por: Schnell, Oliver, et al.
Publicado: (2017) -
Correction to: Updates on cardiovascular outcome trials in diabetes
por: Schnell, Oliver, et al.
Publicado: (2017) -
Type 1 diabetes and cardiovascular disease
por: Schnell, Oliver, et al.
Publicado: (2013) -
Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
por: Schnell, Oliver, et al.
Publicado: (2020) -
Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
por: Schnell, Oliver, et al.
Publicado: (2016)